Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial

Lynn G Feun, Christopher B O'Brien, Enrique Molina, Miguel Rodriguez, Lennox J Jeffers, Eugene R Schiff, Angela Marini, Niramol Savaraj, Bach Ardalan

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)17-20
Number of pages4
JournalJournal of Cancer Research and Clinical Oncology
Volume129
Issue number1
StatePublished - Jan 1 2003

Fingerprint

Interferon-alpha
Doxorubicin
Hepatocellular Carcinoma
Interferons
Chills
Combination Drug Therapy
Fatigue
Fever

Keywords

  • 5FUDR
  • Doxorubicin
  • Hepatocellular carcinoma
  • Interferon

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. / Feun, Lynn G; O'Brien, Christopher B; Molina, Enrique; Rodriguez, Miguel; Jeffers, Lennox J; Schiff, Eugene R; Marini, Angela; Savaraj, Niramol; Ardalan, Bach.

In: Journal of Cancer Research and Clinical Oncology, Vol. 129, No. 1, 01.01.2003, p. 17-20.

Research output: Contribution to journalArticle

@article{991d6f2575a94a0882d5d2eba1be7e2b,
title = "Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial",
abstract = "Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7{\%}) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.",
keywords = "5FUDR, Doxorubicin, Hepatocellular carcinoma, Interferon",
author = "Feun, {Lynn G} and O'Brien, {Christopher B} and Enrique Molina and Miguel Rodriguez and Jeffers, {Lennox J} and Schiff, {Eugene R} and Angela Marini and Niramol Savaraj and Bach Ardalan",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "129",
pages = "17--20",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial

AU - Feun, Lynn G

AU - O'Brien, Christopher B

AU - Molina, Enrique

AU - Rodriguez, Miguel

AU - Jeffers, Lennox J

AU - Schiff, Eugene R

AU - Marini, Angela

AU - Savaraj, Niramol

AU - Ardalan, Bach

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.

AB - Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.

KW - 5FUDR

KW - Doxorubicin

KW - Hepatocellular carcinoma

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=0037249292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037249292&partnerID=8YFLogxK

M3 - Article

C2 - 12618896

AN - SCOPUS:0037249292

VL - 129

SP - 17

EP - 20

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 1

ER -